TOKYO - A Japanese health ministry panel on Monday approved Moderna Inc.'s COVID-19 vaccine for ages 12 to 17, clearing the way for it to become the second shot available to adolescents in the country after the one developed by Pfizer Inc.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
